Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.
We recently had the honor of speaking with the EACR President and Conference Chair Anton Berns (Netherlands Cancer Institute, Amsterdam) about his highlights from the 25th Biennial Congress of the EACR.
First-time evidence that individuals at risk of developing AML can be identified, years before diagnosis
Researchers have discovered that it is possible to identify individuals at high risk of developing acute myeloid leukaemia years before diagnosis.
Researchers have uncovered a key mechanism that drives hormone therapy resistance in prostate cancer.
The prostate cancer test combines genetic variations linked to prostate cancer and identifies the 1% of men that are at high risk.
In this new article published in Future Oncology, Ottoboni et al. report on the safety of a novel and recently FDA-approved polysorbate 80‒ and synthetic surfactant‒free intravenous formulation of the neurokinin 1 receptor antagonist aprepitant (HTX-019).
We have brought together our top takeaways from the five days of ASCO 2018.
Discover the highlights and key presentations from the second day of the the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
A genomic study has demonstrated that individuals with tumors that have high-microsatellite instability (MSI-H) are more likely to have Lynch syndrome.
ASCO18: Prostate cancer survival in black men following chemotherapy may be as good, or better, as in white men
Analysis of data from more than 8000 men with advanced prostate cancer who received chemotherapy suggests survival chances for black men are at least as good as those for white men when provided with equal treatment.